An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity

References

• [cited 2020 Feb 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
   Google Scholar
• Reiner Ž. PCSK9 inhibitors–past, present and future. Expert Opin Drug Metab Toxicol. 2015;11:1517–1521.
   Google Scholar
• Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25:387–393.
   Google Scholar
• Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018;57:769–779.
   Google Scholar
• Gibbs JP, Doshi S, Kuchimanchi M, et al. Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9). J Clin Pharmacol. 2017;57(5):616–626.
   Google Scholar
• Busuioc MR. Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy. Nephrol Dial Transplant. 2019;1–12. DOI: 10.1093/ndt/gfz108.
   Google Scholar
• Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to pcsk9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014 Dec;32(6):297–301. .
   Google Scholar
• Praluent® (alirocumab). Summary of product characteristics (EC); 2015. Available from: http://ec.europa.eu/health/documents/community-register/2015/20150923132812/anx_132812_en.pdf. cited 2020 Apr 3
   Google Scholar
• Gragnano F, Concilio C, Cesaro A, et al. Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy. Eur Heart J. 2017;38(Supplement 1):314.
   Google Scholar
• Saborowski M, Dölle M, Manns MP, et al. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohort. Cardiol J. 2018;25(1):32–41. .
   Google Scholar
• Robinson JG, Farnier M, Krempf M, et al., Odyssey Long Term Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499.
   Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
   Google Scholar
• FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Silver Spring, MD: Food and Drug Administration; 2012 February 28. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
   Google Scholar
• Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013 Nov;88(11):1213–1221. .
   Google Scholar
• Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the statin cognitive safety task force: 2014 update. J Clin Lipidol. 2014;8(Suppl):S5–S16. .
   Google Scholar
• Open-Label Study of Long-Term Evaluation against LDL Cholesterol Investigators: Sabatine MS, Giugliano RP, Wiviott SD. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015b;372:1500–1509.
   Google Scholar
• Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. Aaps J. 2010;12(1):33–43.
   Google Scholar
• Giugliano RP, Mach F, Zavitz K, et al. for the EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633–643.
   Google Scholar
• Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J Immunol Res. 2016;2016:1298473.
   Google Scholar
• Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol. 2019;74:2132–2146.
   Google Scholar
• Harvey PD, Sabbagh MN, Harrison JE, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: meta-analysis of individual patient data. Eur Heart J. 2018;39:374–381.
   Google Scholar
• Gencer B, Mach F. So low … so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. Eur Heart J. 2018 February 01;39(5):382–384.
   Google Scholar
• Farnier M, Hovingh GK, Langslet G, et al. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program. Atherosclerosis. 2018 Nov;278:307–314.
   Google Scholar
• Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019:1–9.
   Google Scholar
• Banach M, Rizzo M, Nikolic D, et al. Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol Ther. 2017 Feb;170:181–191.
   Google Scholar
• Leiter LA, Tinahones FJ, Karalis DG, et al. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742–1751. .
   Google Scholar
• Leiter LA, Cariou B, Muller-Wieland D, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN trial. Diabetes Obes Metab. 2017;19:1781–1792.
   Google Scholar
• Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144–2153.
   Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497–2506.
   Google Scholar
• for the GAUSS-2 Investigators: Stroes E, Colquhoun D, Sullivan D. et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541–2548.
   Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al., Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580–1590.
   Google Scholar
• Rosenson R, Hegele RA, Fazio S, et al. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018 Jul 17;72(3):314–329.
   Google Scholar
• Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:554–561.
   Google Scholar
• Gaudet D, Langslet G, Gidding SS, et al. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study. J Clin Lipidol. 2018 Sep - Oct;12(5):1199–1207. .
   Google Scholar
• Yandrapalli S, Gupta S, Andries G, et al. Drug therapy of dyslipidemia in the elderly. Drugs Aging. 2019;36:321–340.
   Google Scholar
• Anagnostis P, Vaitsi K, Veneti S, et al. Management of dyslipidaemias in the elderly population—A narrative review. Maturitas. 2019;124:93–99.
   Google Scholar
• Paciullo F, Fallarino F, Bianconi V, et al. PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. J Cell Physiol. 2017;232:2330–2338.
   Google Scholar
• Jamialahmadi T, Panahi Y, Safarpour MA, et al. Association of serum PCSK9 levels with antibiotic resistance and severity of disease in patients with bacterial infections admitted to intensive care units. J Clin Med. 2019 Oct 20;8(10). DOI:10.3390/jcm8101742.
   Google Scholar
• Antalis CJ, Uchida A, Buhman KK, et al. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Expl Meta. 2011;28:733–741.
   Google Scholar
• Momtazi-Borojeni AA, Nik ME, Jaafari MR, et al. Effects of immunization against PCSK9 in an experimental model of breast cancer. Arch Med Sci. 2019;15(3):570–579. .
   Google Scholar
• Momtazi-Borojeni AA, Nik ME, Jaafari MR, et al. Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer. Arch Med Sci. 2019;15(3):559–569.
   Google Scholar
• Orth M, Bellosta S. Cholesterol: its regulation and role in central nervous system disorders. Cholesterol. 2012;2012:292598.
   Google Scholar
• Mannarino MR, Sahebkar A, Bianconi V, et al. PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS Q1 results? J Clin Lipidol. 2018 Sep - Oct;;12(5):1123–1132.
   Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–950.
   Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   Google Scholar